Cargando…

Influence of SLCO1B1 521T>C, UGT2B7 802C>T and IMPDH1 −106G>A Genetic Polymorphisms on Mycophenolic Acid Levels and Adverse Reactions in Chinese Autoimmune Disease Patients

INTRODUCTION: Mycophenolate mofetil (MMF), a new type of immunosuppressant, has emerged as a frontline agent for treating autoimmune diseases. Mycophenolic acid (MPA) is an active metabolite of MMF. MPA exposure varies greatly among individuals, which may lead to adverse drug reactions such as gastr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shu, Qing, Fan, Qingqing, Hua, Bingzhu, Liu, Hang, Wang, Shiying, Liu, Yunxing, Yao, Yao, Xie, Han, Ge, Weihong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233479/ https://www.ncbi.nlm.nih.gov/pubmed/34188518 http://dx.doi.org/10.2147/PGPM.S295964

Ejemplares similares

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users
por: Jansen, Marleen E., et al.
Publicado: (2023)

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
por: Dou, Ye, et al.
Publicado: (2015)

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism
por: Zeng, Weiwei, et al.
Publicado: (2022)

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
por: Park, Jin-Woo, et al.
Publicado: (2022)

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case–Control Studies
por: Hou, Qingtao, et al.
Publicado: (2015)

Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis
por: Jiang, Jiajia, et al.
Publicado: (2016)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia
por: Bai, Jie, et al.
Publicado: (2019)

Associations between UGT1A1 and SLCO1B1 polymorphisms and susceptibility to neonatal hyperbilirubinemia in Thai population
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
por: Tague, Laneshia K., et al.
Publicado: (2019)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

Expression of IMPDH mRNA after Mycophenolate Administration in Male Volunteers
por: Kim, Sollip, et al.
Publicado: (2014)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

c‐Myc–IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming
por: Zhang, Qiang, et al.
Publicado: (2023)

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
por: Stewart, Alison
Publicado: (2013)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
por: Taylor, Zachary L., et al.
Publicado: (2021)

SLCO1B1 c.388A > G variant incidence and the severity of hyperbilirubinemia in Indonesian neonates
por: Amandito, Radhian, et al.
Publicado: (2019)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
por: Prado, Yalena, et al.
Publicado: (2015)

Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China
por: Liu, Jiebo, et al.
Publicado: (2013)

Pharmacogenomic-guided clozapine administration based on HLA-DQB1, HLA-B and SLCO1B3-SLCO1B7 variants: an effectiveness and cost-effectiveness analysis
por: Ninomiya, Kohei, et al.
Publicado: (2022)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms
por: Pithukpakorn, Manop, et al.
Publicado: (2014)

Association of gallstone and polymorphisms of UGT1A1*27 and UGT1A1*28 in patients with hepatitis B virus-related liver failure
por: Zhuo, Haiyan, et al.
Publicado: (2022)

SLCO1B1 genetic variation and hormone therapy in menopausal women
por: Moyer, Ann M., et al.
Publicado: (2018)

Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
por: Shchulkin, Aleksey V., et al.
Publicado: (2023)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
por: Romero-Lorca, Alicia, et al.
Publicado: (2015)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients
Publicado: (2015)

The Emerging Role of the SLCO1B3 Protein in Cancer Resistance
por: Sun, Ruipu, et al.
Publicado: (2020)

Influence of SLCO1B1 in gastric cancer patients treated with EOF chemotherapy
por: Feng, Wanjing, et al.
Publicado: (2018)

SLCO1B1 and ABCG2 Gene Polymorphisms in a Thai Population
por: Rattanacheeworn, Punyabhorn, et al.
Publicado: (2020)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
por: Rodrigues, Alice C., et al.
Publicado: (2011)

Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants
por: Lönnberg, K. Ivar, et al.
Publicado: (2023)

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition
por: Ni, Wenjun, et al.
Publicado: (2010)

Loss of SLCO1B3 drives taxane resistance in prostate cancer
por: de Morrée, Ellen S, et al.
Publicado: (2016)

Developmental Pharmacogenetics of SLCO2B1 on Montelukast Pharmacokinetics in Chinese Children
por: Li, Qian, et al.
Publicado: (2019)

An integrated pharmacokinetic/pharmacogenomic analysis of ABCB1 and SLCO1B1 polymorphisms on edoxaban exposure
por: Vandell, A G, et al.
Publicado: (2018)

Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients
por: Mazidi, Talia, et al.
Publicado: (2013)

Role of lncSLCO1C1 in gastric cancer progression and resistance to oxaliplatin therapy
por: Xiao, Yu‐Feng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jgagrmqvsjkse28tc3g0hrepep